Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

HTDS
Sort by: Date|Relevance

The Right Tools at the Right Time to Control Crop Disease & Boost Yields

Download the episode here . Agri-tech Company Bee Vectoring Technologies International Inc. ( TSX-V: BEE , OTCQB: BEVVF , Forum ) has pioneered a unique and natural precision agriculture system that uses commercially-grown bees to deliver biological crop ...
Stockhouse Media | July 16, 2020 |

Alzheimer’s Breakthrough: Why the Experts are Betting on NervGen

It's the disease that most of us regard with the greatest dread – especially since nearly one in every three people will eventually be afflicted. This is why a breakthrough pharmaceutical drug for Alzheimer’s disease would not only be a godsend to society,...
Marc Davis | April 7, 2021 |

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...
Streetwise Reports | December 19, 2019 |

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. Neurodegen...
Streetwise Reports | December 9, 2019 |

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...
Marc Davis | February 7, 2020 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...
Streetwise Reports | October 18, 2019 |

Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data

Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease. Clinical-stage biotechnology company Cassava Sciences Inc. (SAVA:NASDAQ) , which focuses on neurodegenerative di...
Streetwise Reports | June 4, 2020 |

Immunotherapeutic Agent Shows Efficacy in Rare Respiratory Disease

Trial results for this therapeutic, and their implications for this biotech, were discussed in an H.C. Wainwright & Co. report. In an April 4 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Inovio Pharmaceuticals Inc.'s (INO:NASDA...
Streetwise Reports | April 11, 2019 |

Eton Pharma Shares Climb 20% After Firm Secures US Rights for Pediatric Kidney Disease Drug

Shares of Eton Pharmaceuticals traded higher after the company reported that it has acquired U.S. marketing rights to pediatric orphan drug Alkindi® Sprinkle from Diurnal Group Plc. Eton Pharmaceuticals Inc. (ETON:NASDAQ) , which is focused on devel...
Streetwise Reports | March 30, 2020 |
1 2 3 4 5 6 7 8 9 10 ...